A Agilent Technologies Inc.

Agilent Included in Just Capital’s 2023 List of Most Just Companies

Agilent Technologies Inc. (NYSE: A) is ranked 35 among the , the fifth year the company has been included in the annual list by Just Capital and CNBC. Agilent also earned the top ranking in its sector for industry-leading performance regarding treatment of employees, customers and the environment.

Just Capital and CNBC on a review of the policies and practices of 1,000 of the largest U.S. public companies on issues that matter most to Americans, including wages and benefits, job creation, worker health and safety, ethical leadership, and environmental stewardship.

Agilent’s top ranking on worker issues reflects its commitment to being an employer of choice globally. In 2022, Agilent earned , including the United States, and was recently ranked among the .

Just Capital also ranked Agilent number one in the industry for its treatment of customers. For the past two years, Agilent has ranked in the in customer satisfaction by the Wall Street Journal and the Drucker Institute’s annual list of the best-managed companies.

“Agilent employees work closely with our customers to bring great science to life and to carry out our mission to advance the quality of life,” said Neil Rees, Agilent’s head of Environmental, Social, and Governance (ESG) Programs. “Treating our employees well and creating products that help our customers improve human health and reduce environmental impact are essential to our ESG commitment.”

Agilent has reported on its corporate responsibility practices for over 20 years. The company is included in the JUST U.S. Large Cap Diversified (JULCD) Index and the Dow Jones Sustainability Indices (DJSI). Read more about Agilent’s commitment to , , and other .

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the . Follow Agilent on and .

EN
18/01/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch